Plurality of tasquinimod particles and use thereof
A plurality of particles of tasquinimod in free base form or as a pharmaceutically acceptable salt, said particles having a D(v, 0.9) of at most 30 pm and a D(v, 0.5) of at most 15 μm. A pharmaceutical composition comprising said particles and preferably one or more pharmaceutically acceptable excipients. A pharmaceutical dosage unit. The particles, composition and dosage unit are useful in the treatment of cancer.
1 . A plurality of particles comprising tasquinimod in free base form or as a pharmaceutically acceptable salt, said particles having a D (v,0.9) of at most 30 μm and a D (v,0.5) of at most 15 μm.
2 . The plurality of particles of claim 1 , wherein said particles have a D (v,0.9) of at most 25 μm, and a D (v,0.5) in the range of 2 μm to 9 μm.
3 . The plurality of particles of claim 1 , wherein said particles have a D (v,0.5) in the range of 3 to 7 μm.
4 . A pharmaceutical composition comprising the plurality of particles of claim 1 , and one or more pharmaceutically acceptable excipients.
5 . The pharmaceutical composition of claim 4 , comprising said plurality of particles in an amount of from 0.1 to 10% by weight of the composition.
6 . The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable excipients comprise a filler and a lubricant.
7 . A pharmaceutical dosage unit comprising the pharmaceutical composition of claim 4 .
8 . The pharmaceutical dosage unit of claim 7 , containing the plurality of particles in an amount in the range of 0.1 mg to 2 mg.
9 . The pharmaceutical dosage unit of claim 7 , for oral administration.
10 . The pharmaceutical dosage unit of claim 9 , which is a capsule or tablet.
11 . The pharmaceutical dosage unit of claim 7 , which is an immediate-release pharmaceutical dosage unit.
12 . A method for the treatment of cancer by administering, to a mammal in need of such treatment, a therapeutically effective amount of the plurality of particles of claim 1 .
13 . The method of claim 12 , wherein the cancer is a hematologic cancer.
14 . The method of claim 13 , wherein the hematological cancer is selected from multiple myeloma, lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm, and leukemia.
15 . The method of claim 12 , wherein the cancer is a solid cancer.
16 . The method of claim 15 , wherein the solid cancer is selected from bladder cancer, melanoma, lung cancer, colorectal cancer, breast cancer, pancreatic cancer, prostate cancer, renal cell carcinoma, ovarian cancer, neuroendocrine tumors (NET) and gastroenteropancreatic neuroendocrine tumors (GEP-NET).
17 . The pharmaceutical dosage unit of claim 7 , containing the plurality of particles in an amount in the range of 0.2 mg to 1 mg.